 |
|
|
| |
Patient-Reported Outcomes After 152 Weeks of HIV Maintenance Therapy With Long-Acting Cabotegravir + Rilpivirine in the Phase 3b ATLAS-2M Study
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Vasiliki Chounta1, Edgar T. Overton2, Sebastian Noe3, Susan Swindells4, Eugenia Negredo5, Ronald D'Amico6, Conn Harrington6, Simon Vanveggel7,
Rodica Van Solingen-Ristea7, Yuanyuan Wang8, Carolina Acuipil6, William R. Spreen6
1ViiV Healthcare, Brentford, United Kingdom; 2University of Alabama at Birmingham, Birmingham, AL, United States; 3MVZ München am Goetheplatz, Munich, Germany;
4University of Nebraska Medical Center, Omaha, NE, United States; 5Germans Trias i Pujol University Hospital, Barcelona, Spain; 6ViiV Healthcare, Research Triangle Park, NC, United States;
7Janssen Research & Development, Beerse, Belgium; 8GlaxoSmithKline, Collegeville, PA, United States
|
| |
|
|
|
|
|
